Paxman AB (publ) (PAX.ST)
SEK 65.0
(0.0%)
SEK 65.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 167.12 Million SEK | -3.93% |
| 2022 | 173.96 Million SEK | 4.58% |
| 2021 | 166.34 Million SEK | 116.0% |
| 2020 | 77.01 Million SEK | -9.37% |
| 2019 | 84.97 Million SEK | 52.45% |
| 2018 | 55.73 Million SEK | 22.22% |
| 2017 | 45.6 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 183.85 Million SEK | 10.01% |
| 2024 Q2 | 190.33 Million SEK | 3.53% |
| 2023 Q4 | 167.12 Million SEK | -8.03% |
| 2023 Q3 | 181.72 Million SEK | 3.53% |
| 2023 FY | 167.12 Million SEK | -3.93% |
| 2023 Q1 | 169.01 Million SEK | -2.84% |
| 2023 Q2 | 175.53 Million SEK | 3.86% |
| 2022 Q3 | 176.58 Million SEK | 6.14% |
| 2022 FY | 173.96 Million SEK | 4.58% |
| 2022 Q1 | 161.47 Million SEK | -2.93% |
| 2022 Q4 | 173.96 Million SEK | -1.49% |
| 2022 Q2 | 166.37 Million SEK | 3.04% |
| 2021 Q3 | 114.95 Million SEK | -4.27% |
| 2021 Q4 | 166.34 Million SEK | 44.7% |
| 2021 FY | 166.34 Million SEK | 116.0% |
| 2021 Q1 | 120.97 Million SEK | 57.09% |
| 2021 Q2 | 120.07 Million SEK | -0.74% |
| 2020 FY | 77.01 Million SEK | -9.37% |
| 2020 Q3 | 87.21 Million SEK | 0.83% |
| 2020 Q4 | 77.01 Million SEK | -11.69% |
| 2020 Q2 | 86.49 Million SEK | -8.4% |
| 2020 Q1 | 94.42 Million SEK | 11.12% |
| 2019 Q4 | 84.97 Million SEK | 14.99% |
| 2019 Q3 | 73.89 Million SEK | 5.32% |
| 2019 Q1 | 62.11 Million SEK | 11.43% |
| 2019 FY | 84.97 Million SEK | 52.45% |
| 2019 Q2 | 70.16 Million SEK | 12.96% |
| 2018 Q3 | 51.06 Million SEK | 12.51% |
| 2018 FY | 55.73 Million SEK | 22.22% |
| 2018 Q1 | 43.71 Million SEK | -4.15% |
| 2018 Q4 | 55.73 Million SEK | 9.15% |
| 2018 Q2 | 45.38 Million SEK | 3.83% |
| 2017 FY | 45.6 Million SEK | 0.0% |
| 2017 Q2 | 64.65 Million SEK | 152.04% |
| 2017 Q1 | 25.65 Million SEK | 0.0% |
| 2017 Q4 | 45.6 Million SEK | -27.29% |
| 2017 Q3 | 62.72 Million SEK | -2.98% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | -165.767% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 94.916% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 94.916% |
| Arcoma AB | 81.96 Million SEK | -103.905% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | 75.526% |
| BICO Group AB (publ) | 10.19 Billion SEK | 98.361% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | 77.867% |
| CellaVision AB (publ) | 928.71 Million SEK | 82.005% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | -189.519% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -661.2% |
| C-Rad AB (publ) | 404 Million SEK | 58.632% |
| Duearity AB (publ) | 15.14 Million SEK | -1003.572% |
| Dignitana AB (publ) | 44.83 Million SEK | -272.789% |
| Episurf Medical AB (publ) | 104.3 Million SEK | -60.235% |
| Getinge AB (publ) | 55.09 Billion SEK | 99.697% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | -62.829% |
| Iconovo AB (publ) | 128.07 Million SEK | -30.485% |
| Integrum AB (publ) | 164.85 Million SEK | -1.374% |
| Luxbright AB (publ) | 40.68 Million SEK | -310.761% |
| Mentice AB (publ) | 322.52 Million SEK | 48.182% |
| OssDsign AB (publ) | 356.38 Million SEK | 53.106% |
| Promimic AB (publ) | 92.87 Million SEK | -79.946% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -328.021% |
| SciBase Holding AB (publ) | 64.33 Million SEK | -159.777% |
| ScandiDos AB (publ) | 81.47 Million SEK | -105.129% |
| Sectra AB (publ) | 3.21 Billion SEK | 94.795% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 83.519% |
| Senzime AB (publ) | 433.54 Million SEK | 61.451% |
| SpectraCure AB (publ) | 144.83 Million SEK | -15.391% |
| Stille AB | 804.89 Million SEK | 79.236% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 98.98% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 92.388% |